Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

KB 141

Known as: KB-141, KB141 cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Mutations in thyroid hormone receptors (TRs) often lead to metabolic and developmental disorders, but patients with these… 
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2012
2012
Subtype‐selective thyromimetics have potential as new pharmaceuticals for the prevention or treatment of heart disease, high LDL… 
Highly Cited
2008
Highly Cited
2008
Selective thyroid hormone receptor subtype-beta (TRbeta) agonists have received attention as potential treatments for… 
Review
2008
Review
2008
The processes and pathways mediating the intermediary metabolism of carbohydrates, lipids, and proteins are all affected by… 
Highly Cited
2007
Highly Cited
2007
Despite efforts spanning four decades, the therapeutic potential of thyroid hormone receptor (TR) agonists as lipid-lowering and… 
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Review
2007
Review
2007
Obesity and metabolic syndrome are increasing dramatically worldwide, contributing to cardiovascular morbidity and mortality… 
2007
2007
Based on the scaffold of the pharmacologically selective thyromimetic 2b, structurally a close analog to KB-141 (2a), a number of… 
2006
2006
Based on the examination of the X-ray crystallographic structures of the LBD of TRalpha and TRbeta in complex with KB-141 (2), a… 
Review
2005
Review
2005
Few treatments for obesity exist and improvements for treatment of hyperlipidemia are still desirable. Thyroid hormone receptors… 
Highly Cited
2003
Highly Cited
2003
Few treatments for obesity exist and, whereas efficacious therapeutics for hyperlipidemia are available, further improvements are… 
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • table 1